Zepbound was a breakthrough. It became the first medicine to mimic the GLP-1 and GIP gut hormones and be approved for weight ...
Microsoft isn't always the first company that comes up when AI investments are discussed.
At its current pace, the software giant could spend it all before 2030. What might that do to earnings per share?
Over his career, Warren Buffett established himself as one of the world's best investors. However, after 60 years at ...
Since 1945, the U.S. stock market has endured 37 corrections (declines of 10% or more), according to data from MUFG. These 10 ...
Cameco's stock has fallen from $134 to $85, but that drop could be an opportunity for investors looking to invest in nuclear ...
And this spring, Lilly won regulatory approval for Foundayo. All three are part of a class of drugs known as GLP-1. These ...
Rocket Lab ( RKLB +4.91%) signed a deal for 20 new Electron launches with Japanese radar-satellite operator Synspective late ...
The S&P 500 yields only around 1%, but there's still a path for using it to create hundreds of dollars a month in dividend ...
CoreWeave's AI-ready cloud infrastructure is in high demand, but keeping up with it is an expensive proposition.
Grail received some excellent news from the FDA this week, but there's still a long way to go before the company meets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results